Developer docs
API playgroundTry for free, no card

Search company profiles

SciRhom

Full company profile

uuid0000t5a

Namestring
SciRhom
Legal namestring
SciRhom GmbH
Websiteurl
scirhom.com
Company typeenum
Private
Founded yearint
2016
Descriptiontext

SciRhom GmbH is a privately held, clinical-stage biopharmaceutical company founded in 2016 in Martinsried, Germany, that develops first-in-class humanized monoclonal antibodies targeting iRhom2 (inactive Rhomboid 2 / RHBDF2), a key upstream regulator of the TACE/ADAM17 protease. By inhibiting iRhom2 selectively in immune cells, the company's lead candidate SR-878 simultaneously blocks multiple established pro-inflammatory pathways — TNF-alpha, IL-6R, and EGFR/HB-EGF signaling — while preserving protective TACE functions in epithelial tissues, a profile designed to address the 30-40% of autoimmune patients who do not adequately respond to existing biologics. SciRhom is developing SR-878 and the broader Anti-iRhom2 Antibody Platform for rheumatoid arthritis, inflammatory bowel disease, lupus nephritis, and dermatological indications, with first-in-human dosing initiated in October 2024 in Austria and a Phase 1 readout expected in H2 2025.

The company is pre-revenue and monetizes via eventual commercialization of approved antibody products through traditional pharmaceutical channels; currently it funds operations almost entirely through venture capital, having raised approximately EUR 79 million to date (EUR 16M seed plus an oversubscribed EUR 63M Series A in July 2024 co-led by Andera Partners, Kurma Partners, Hadean Ventures, MIG Capital, and Wellington Partners). SciRhom's go-to-market posture is enterprise-oriented, relying on academic medical centers for clinical development (e.g., Medical University of Vienna), WuXi Biologics for CMC and manufacturing, and a Clinical Advisory Board of leading rheumatologists for scientific and clinical guidance. Four granted patent families protect the iRhom2-targeting technology, and the management team combines Max Planck/U3 Pharma/Daiichi Sankyo antibody development pedigree with senior commercial and clinical leadership from Boehringer Ingelheim.

Customer relationships are forward-looking: there are no commercial customers today, and end-users are patients with autoimmune diseases (segmented primarily as autoimmune disease patients and secondarily as dermatological disease patients) who will access the therapy only after regulatory approval and commercialization. The target end-markets are large, fragmented therapeutic categories in which SciRhom will compete against established biologics (anti-TNF, anti-IL-6R) on the basis of multi-pathway inhibition and a differentiated safety profile.

Short descriptiontext

SciRhom GmbH is a clinical-stage German biotech developing first-in-class anti-iRhom2 monoclonal antibody therapies for patients with autoimmune diseases such as rheumatoid arthritis, inflammatory bowel disease, and lupus nephritis.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMartinsried, Germany
HQ citystring
Martinsried
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
monoclonal antibody therapies, autoimmune disease therapeutics, iRhom2 antibody platform, clinical-stage biopharmaceuticals, inflammatory disease biologics
Industry2 codes
PRIMARYHLAAAAAB
Recombinant Protein Therapeutics (enzymes, hormones, growth factors)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIAIAB
Enzyme Replacement & Metabolic Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biopharmaceutical Antibody Therapeutics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Sales
TypeOne Time License
Description

Pre-revenue company developing antibody therapies for autoimmune diseases. Revenue will be generated through commercialization of approved therapeutic products, initially targeting rheumatoid arthritis, inflammatory bowel disease, and lupus nephritis.

scirhom.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

SciRhom is a clinical-stage biotech developing first-in-class humanized monoclonal antibodies that target iRhom2 (RHBDF2), a key regulator of the TACE/ADAM17 protease. Its lead candidate SR-878 simultaneously blocks multiple pro-inflammatory pathways (TNF-alpha, IL-6R, EGFR) while preserving protective TACE functions, and is being advanced through Phase 1 clinical trials for rheumatoid arthritis, inflammatory bowel disease, and lupus nephritis. The company also maintains a broader Anti-iRhom2 Antibody Platform protected by four patent families as the foundation for follow-on programs.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Addresses the 30-40% of autoimmune patients who do not respond to existing biologics
+2 more records
Product overview1 text field

SciRhom is a biopharmaceutical company developing first-in-class iRhom2-targeting antibody therapies for autoimmune diseases. The company's core product is SR-878, a monoclonal antibody currently in Phase 1 clinical development, supported by the Anti-iRhom2 Antibody Platform which underlies the therapeutic approach. The platform enables targeting of iRhom2/TACE pathway to simultaneously block TNF-alpha, IL-6R, and EGFR signaling while preserving protective functions. Development pipeline includes rheumatoid arthritis, inflammatory bowel disease, lupus nephritis, and dermatological diseases.

Product and service2 records
1SR-878
CategoryAntibody Therapeutic / Lead Clinical Candidate
Description

A first-in-class humanized monoclonal antibody targeting iRhom2 (inactive Rhomboid 2/RHBDF2), designed to simultaneously block multiple pro-inflammatory signaling pathways including TNF-alpha, IL-6R, and EGFR while preserving protective functions of TACE/ADAM17. Currently in Phase 1 clinical development for autoimmune diseases including rheumatoid arthritis, inflammatory bowel disease, and lupus nephritis.

2Anti-iRhom2 Antibody Platform
CategoryAntibody Discovery Platform / Proprietary Technology
Description

Proprietary platform technology for developing first-in-class therapeutic antibodies targeting iRhom2, a critical regulator of TACE/ADAM17. The platform enables simultaneous blockade of multiple pro-inflammatory pathways with an expected favorable safety profile compared to direct TACE inhibitors. Four patent families protect the technology and provide exclusivity against follow-on drugs.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
1Prof. Carl Blobel / Hospital for Special Surgery
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Co-founder of SciRhom. Prof. Blobel made seminal contributions to understanding how iRhom2 controls TACE/ADAM17 activity. His research at Hospital for Special Surgery in New York City formed the scientific foundation for SciRhom's anti-iRhom2 antibodies.

scirhom.com
Strategic tierCoreTypeTechnology or Integration
Description

Top-tier biopharmaceutical manufacturer engaged for CMC development and manufacturing of SR-878 clinical candidate. Established robust biopharmaceutical manufacturing process producing high yields with excellent antibody properties.

3Medical University of Vienna
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Clinical trial partnership for first-in-human study of SR-878. The Department of Clinical Pharmacology at Medical University of Vienna is conducting the Phase 1 clinical trial.

scirhom.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Specialty immunology company marketing Cimzia (certolizumab, anti-TNF) and Rinvoq (JAK inhibitor) in RA, IBD, and other autoimmune indications. Competes in the same autoimmune disease space SciRhom is targeting.

TypeBroad incumbent
Description

Global biopharmaceutical company with Humira (adalimumab) and Skyrizi/Rinvoq in autoimmune diseases, the dominant TNF-alpha inhibitor franchise that SciRhom's anti-iRhom2 antibodies aim to outperform in RA/IBD patients with inadequate response.

TypeBroad incumbent
Description

Markets Stelara, Tremfya, and Remicade in autoimmune diseases including RA, IBD, and lupus. A leading incumbent whose IL-12/23 and IL-23 inhibitors compete directly for the autoimmune patient population SciRhom targets.

TypeBroad incumbent
Description

Markets Actemra (tocilizumab, anti-IL-6R) in RA and other autoimmune indications. Directly comparable because SciRhom's anti-iRhom2 antibodies block IL-6R signaling (among other pathways) as part of a multi-pathway mechanism.

TypeBroad incumbent
Description

Markets Enbrel (etanercept, TNF inhibitor) and Otezla (PDE4 inhibitor) in RA, psoriasis, and IBD. Competes in the autoimmune space SciRhom addresses and has deep rheumatology commercial capabilities.

TypeEmerging player
Description

Clinical-stage immunology biotech with lead FcRn antagonist Vyvgart (efgartigimod) approved in autoimmune indications, advancing a pipeline of antibody therapeutics for autoimmune disease — comparable to SciRhom as a focused autoimmune antibody developer.

TypeEmerging player
Description

Clinical-stage antibody therapeutics company developing immunology-focused programs (rosnilimab, ANB033) for autoimmune and inflammatory diseases, with a similar biotech-stage profile and antibody-platform approach to SciRhom.

TypeBroad incumbent
Description

Markets Dupixent (dupilumab, anti-IL-4R) in multiple autoimmune and inflammatory indications including atopic dermatitis and IBD. A relevant incumbent competing for the autoimmune patient segments SciRhom ultimately aims to serve.

TypeBroad incumbent
Description

Markets Olumiant (baricitinib, JAK inhibitor) and Taltz (ixekizumab, anti-IL-17) in RA and other autoimmune indications. Active acquirer of autoimmune biotechs (e.g., Dice Therapeutics) and a potential strategic partner or competitor for SciRhom.

10Bristol Myers Squibb
TypeBroad incumbent
Description

Markets Zeposia (S1P modulator) and Sotyktu (TYK2 inhibitor) in autoimmune diseases including IBD and psoriasis. A relevant incumbent in the autoimmune space and a frequent partner/acquirer of clinical-stage biotechs.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

SciRhom

Biopharmaceutical Antibody Therapeuticsscirhom.com

SciRhom GmbH is a clinical-stage German biotech developing first-in-class anti-iRhom2 monoclonal antibody therapies for patients with autoimmune diseases such as rheumatoid arthritis, inflammatory bowel disease, and lupus nephritis.

What SciRhom does

SciRhom GmbH is a privately held, clinical-stage biopharmaceutical company founded in 2016 in Martinsried, Germany, that develops first-in-class humanized monoclonal antibodies targeting iRhom2 (inactive Rhomboid 2 / RHBDF2), a key upstream regulator of the TACE/ADAM17 protease. By inhibiting iRhom2 selectively in immune cells, the company's lead candidate SR-878 simultaneously blocks multiple established pro-inflammatory pathways — TNF-alpha, IL-6R, and EGFR/HB-EGF signaling — while preserving protective TACE functions in epithelial tissues, a profile designed to address the 30-40% of autoimmune patients who do not adequately respond to existing biologics. SciRhom is developing SR-878 and the broader Anti-iRhom2 Antibody Platform for rheumatoid arthritis, inflammatory bowel disease, lupus nephritis, and dermatological indications, with first-in-human dosing initiated in October 2024 in Austria and a Phase 1 readout expected in H2 2025.

The company is pre-revenue and monetizes via eventual commercialization of approved antibody products through traditional pharmaceutical channels; currently it funds operations almost entirely through venture capital, having raised approximately EUR 79 million to date (EUR 16M seed plus an oversubscribed EUR 63M Series A in July 2024 co-led by Andera Partners, Kurma Partners, Hadean Ventures, MIG Capital, and Wellington Partners). SciRhom's go-to-market posture is enterprise-oriented, relying on academic medical centers for clinical development (e.g., Medical University of Vienna), WuXi Biologics for CMC and manufacturing, and a Clinical Advisory Board of leading rheumatologists for scientific and clinical guidance. Four granted patent families protect the iRhom2-targeting technology, and the management team combines Max Planck/U3 Pharma/Daiichi Sankyo antibody development pedigree with senior commercial and clinical leadership from Boehringer Ingelheim.

Customer relationships are forward-looking: there are no commercial customers today, and end-users are patients with autoimmune diseases (segmented primarily as autoimmune disease patients and secondarily as dermatological disease patients) who will access the therapy only after regulatory approval and commercialization. The target end-markets are large, fragmented therapeutic categories in which SciRhom will compete against established biologics (anti-TNF, anti-IL-6R) on the basis of multi-pathway inhibition and a differentiated safety profile.

SciRhom firmographics

Firmographics
Name
SciRhom
Legal name
SciRhom GmbH
Website
https://scirhom.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
11–50 employees
Short description
SciRhom GmbH is a clinical-stage German biotech developing first-in-class anti-iRhom2 monoclonal antibody therapies for patients with autoimmune diseases such as rheumatoid arthritis, inflammatory bowel disease, and lupus nephritis.
Ownership category
akta.pro rank

SciRhom industry classification

Industry
Product category
Biopharmaceutical Antibody Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAAAB
Recombinant Protein Therapeutics (enzymes, hormones, growth factors)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIAIAB
Enzyme Replacement & Metabolic Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • Monoclonal antibody therapies
  • Autoimmune disease therapeutics
  • IRhom2 antibody platform
  • Clinical-stage biopharmaceuticals
  • Inflammatory disease biologics

Where SciRhom is headquartered

Location

Headquarters

HQ city
Martinsried
HQ country
Germany
HQ region
Europe

Offices1 record

Markets served

SciRhom business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales

Revenue model

  1. Pharmaceutical Product Sales: Pre-revenue company developing antibody therapies for autoimmune diseases. Revenue will be generated through commercialization of approved therapeutic products, initially targeting rheumatoid arthritis, inflammatory bowel disease, and lupus nephritis.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

SciRhom product offering

Product offering

Core offering

SciRhom is a clinical-stage biotech developing first-in-class humanized monoclonal antibodies that target iRhom2 (RHBDF2), a key regulator of the TACE/ADAM17 protease. Its lead candidate SR-878 simultaneously blocks multiple pro-inflammatory pathways (TNF-alpha, IL-6R, EGFR) while preserving protective TACE functions, and is being advanced through Phase 1 clinical trials for rheumatoid arthritis, inflammatory bowel disease, and lupus nephritis. The company also maintains a broader Anti-iRhom2 Antibody Platform protected by four patent families as the foundation for follow-on programs.

Product overview

SciRhom is a biopharmaceutical company developing first-in-class iRhom2-targeting antibody therapies for autoimmune diseases. The company's core product is SR-878, a monoclonal antibody currently in Phase 1 clinical development, supported by the Anti-iRhom2 Antibody Platform which underlies the therapeutic approach. The platform enables targeting of iRhom2/TACE pathway to simultaneously block TNF-alpha, IL-6R, and EGFR signaling while preserving protective functions. Development pipeline includes rheumatoid arthritis, inflammatory bowel disease, lupus nephritis, and dermatological diseases.

Differentiator

Problem solved

Functional benefit

Products and services

  • SR-878 A first-in-class humanized monoclonal antibody targeting iRhom2 (inactive Rhomboid 2/RHBDF2), designed to simultaneously block multiple pro-inflammatory signaling pathways including TNF-alpha, IL-6R, and EGFR while preserving protective functions of TACE/ADAM17. Currently in Phase 1 clinical development for autoimmune diseases including rheumatoid arthritis, inflammatory bowel disease, and lupus nephritis.
  • Anti-iRhom2 Antibody Platform Proprietary platform technology for developing first-in-class therapeutic antibodies targeting iRhom2, a critical regulator of TACE/ADAM17. The platform enables simultaneous blockade of multiple pro-inflammatory pathways with an expected favorable safety profile compared to direct TACE inhibitors. Four patent families protect the technology and provide exclusivity against follow-on drugs.

Quantifiable outcome

  • Addresses the 30-40% of autoimmune patients who do not respond to existing biologics
  • +2 more outcomes

Companies that use SciRhom

Customer profile

Segments2 records

Ideal customer profiles1 record

SciRhom technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

SciRhom partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • Prof. Carl Blobel / Hospital for Special SurgerycoreStrategic or Co-development PartnerCo-founder of SciRhom. Prof. Blobel made seminal contributions to understanding how iRhom2 controls TACE/ADAM17 activity. His research at Hospital for Special Surgery in New York City formed the scientific foundation for SciRhom's anti-iRhom2 antibodies.
  • WuXi BiologicscoreTechnology or IntegrationTop-tier biopharmaceutical manufacturer engaged for CMC development and manufacturing of SR-878 clinical candidate. Established robust biopharmaceutical manufacturing process producing high yields with excellent antibody properties.
  • Medical University of ViennacoreStrategic or Co-development PartnerClinical trial partnership for first-in-human study of SR-878. The Department of Clinical Pharmacology at Medical University of Vienna is conducting the Phase 1 clinical trial.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

SciRhom competitors and assessment

Company assessment

Broad incumbents

  • UCB: Specialty immunology company marketing Cimzia (certolizumab, anti-TNF) and Rinvoq (JAK inhibitor) in RA, IBD, and other autoimmune indications. Competes in the same autoimmune disease space SciRhom is targeting.
  • AbbVie: Global biopharmaceutical company with Humira (adalimumab) and Skyrizi/Rinvoq in autoimmune diseases, the dominant TNF-alpha inhibitor franchise that SciRhom's anti-iRhom2 antibodies aim to outperform in RA/IBD patients with inadequate response.
  • Johnson & Johnson (Janssen): Markets Stelara, Tremfya, and Remicade in autoimmune diseases including RA, IBD, and lupus. A leading incumbent whose IL-12/23 and IL-23 inhibitors compete directly for the autoimmune patient population SciRhom targets.
  • Roche / Genentech: Markets Actemra (tocilizumab, anti-IL-6R) in RA and other autoimmune indications. Directly comparable because SciRhom's anti-iRhom2 antibodies block IL-6R signaling (among other pathways) as part of a multi-pathway mechanism.
  • Amgen: Markets Enbrel (etanercept, TNF inhibitor) and Otezla (PDE4 inhibitor) in RA, psoriasis, and IBD. Competes in the autoimmune space SciRhom addresses and has deep rheumatology commercial capabilities.
  • Sanofi: Markets Dupixent (dupilumab, anti-IL-4R) in multiple autoimmune and inflammatory indications including atopic dermatitis and IBD. A relevant incumbent competing for the autoimmune patient segments SciRhom ultimately aims to serve.
  • Eli Lilly: Markets Olumiant (baricitinib, JAK inhibitor) and Taltz (ixekizumab, anti-IL-17) in RA and other autoimmune indications. Active acquirer of autoimmune biotechs (e.g., Dice Therapeutics) and a potential strategic partner or competitor for SciRhom.
  • Bristol Myers Squibb: Markets Zeposia (S1P modulator) and Sotyktu (TYK2 inhibitor) in autoimmune diseases including IBD and psoriasis. A relevant incumbent in the autoimmune space and a frequent partner/acquirer of clinical-stage biotechs.

Emerging players

  • argenx: Clinical-stage immunology biotech with lead FcRn antagonist Vyvgart (efgartigimod) approved in autoimmune indications, advancing a pipeline of antibody therapeutics for autoimmune disease — comparable to SciRhom as a focused autoimmune antibody developer.
  • AnaptysBio: Clinical-stage antibody therapeutics company developing immunology-focused programs (rosnilimab, ANB033) for autoimmune and inflammatory diseases, with a similar biotech-stage profile and antibody-platform approach to SciRhom.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

SciRhom social profiles

Digital presence

SciRhom financial estimates

Financial estimate

Revenue estimate

Valuation estimate

SciRhom leadership team

Management profile

Number of profiles

Profiles4 records

SciRhom funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

SciRhom M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SciRhom

What does SciRhom do?

SciRhom is a clinical-stage biotech developing first-in-class humanized monoclonal antibodies that target iRhom2 (RHBDF2), a key regulator of the TACE/ADAM17 protease. Its lead candidate SR-878 simultaneously blocks multiple pro-inflammatory pathways (TNF-alpha, IL-6R, EGFR) while preserving protective TACE functions, and is being advanced through Phase 1 clinical trials for rheumatoid arthritis, inflammatory bowel disease, and lupus nephritis. The company also maintains a broader Anti-iRhom2 Antibody Platform protected by four patent families as the foundation for follow-on programs.

Is SciRhom a public or private company?

SciRhom is a private company. It is classified as venture growth investor backed and is currently operating.

When was SciRhom founded?

SciRhom was founded in 2016. It employs 11 to 50 people.

Where is SciRhom based?

SciRhom is headquartered in Martinsried, Germany, in the Europe region.

How does SciRhom make money?

One revenue line is on record: pharmaceutical Product Sales.

Who are SciRhom's main competitors?

Broad incumbents on record are UCB, AbbVie, Johnson & Johnson (Janssen), Roche / Genentech, Amgen, Sanofi, Eli Lilly and Bristol Myers Squibb. Emerging players are argenx and AnaptysBio.

Does SciRhom have an API?

No public API is recorded for SciRhom.

What industry is SciRhom in?

SciRhom's product category is Biopharmaceutical Antibody Therapeutics. Its primary akta.pro industry code is HLAAAAAB, Recombinant Protein Therapeutics (enzymes, hormones, growth factors), with a secondary code of HLAIAIAB, Enzyme Replacement & Metabolic Disorder Therapies. Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
biopharma-reporter.comSciRhom raises €63M in series A to develop antibodies against autoimmune diseasesSciRhom closed a €63 million Series A round led by Andera Partners, Kurma Partners, Hadean Ventures, MIG Capital, and Wellington Partners. The funds will accelerate development of its lead antibody SR-878, with a first clinical study expected to start in the second half of 2024.FinSMEsSciRhom Raises EUR 63M in Series A FinancingSciRhom, a Munich-based biopharmaceutical company, raised EUR 63M in Series A funding co-led by Andera Partners and others. The company will use the funds to accelerate its iRhom2 antibody program, which has advanced to Phase 1-ready stage. A first clinical study in Austria is planned for the second half of 2024.GlobeNewswireSciRhom Secures EUR 63 Million Series A Financing Round to Accelerate iRhom2-targeting Therapies in Autoimmune DiseasesSciRhom GmbH closed a EUR 63 million Series A financing round to accelerate the clinical development of its lead therapy, SR-878, for autoimmune diseases. The funds will support the upcoming Phase 1 clinical study in Austria, which is expected to begin dosing healthy volunteers in the second half of 2024 following recent regulatory approval.ScirhomSciRhom Secures EUR 63 Million Series A Financing Round to Accelerate iRhom2-targeting Therapies in Autoimmune DiseasesSciRhom GmbH announced the completion of a EUR 63 million Series A financing round, co-led by several investment firms, to advance its lead development program targeting autoimmune diseases. The funding will accelerate the clinical development of its innovative iRhom2-targeting therapies, specifically the monoclonal antibody SR-878, with the first clinical study expected to begin in the second half of 2024. This financing represents a significant step toward addressing the unmet medical need for more effective treatments for autoimmune disorders.FierceBiotechAfter 20 years, Boehringer vet hits the exit to become CEO at autoimmune biotech SciRhomJan Poth left Boehringer Ingelheim after 20 years to become CEO of SciRhom, replacing co-founder Jens Ruhe, who moved to COO. SciRhom, which has a clinical candidate, raised an additional 8 million euros in seed funding to advance its iRhom2 antibody pipeline toward clinical trial application.The Life Science and Biotech NewswireSciRhom Augments Seed Financing to Reach Total Funding of EUR 16 MillionSciRhom GmbH announced an increase of EUR 8 million in seed capital, bringing their total funding to EUR 16 million to advance development towards IND approval for their novel drug candidates aimed at autoimmune diseases. This funding will facilitate further analysis and manufacturing processes as they prepare for applications with regulatory authorities in Europe and the US. The company's drug candidates aim to offer significant improvements over current therapies, especially for patients not responding to existing medications.